Designed ankyrin repeat proteins (DARPins): Binding proteins for research, diagnostics, and therapy

Annual Review of Pharmacology and Toxicology

Volumn 55, Issue , 2015, Pages 489-511

  Plückthun, Andreas ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Directed evolution; Protein engineering; Protein scaffold; Sensors; Tumor targeting; Virus retargeting

Indexed keywords

ANKYRIN; BINDING PROTEIN; DESIGNED ANKYRIN REPEAT PROTEIN; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; DRUG CARRIER; PEPTIDE LIBRARY; RECOMBINANT PROTEIN;

APOPTOSIS; BINDING AFFINITY; CANCER THERAPY; CONFORMATIONAL TRANSITION; CRYSTALLIZATION; DEPOLYMERIZATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYDRODYNAMICS; IMMUNOGENICITY; MACULAR DEGENERATION; MICROTUBULE ASSEMBLY; MOLECULAR LIBRARY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHAGE DISPLAY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN STABILITY; REVIEW; SOLUBILITY; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DIAGNOSTIC USE; DRUG DESIGN; GENE THERAPY; GENETICS; METABOLISM; PEPTIDE LIBRARY; PROCEDURES; STRUCTURE ACTIVITY RELATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANKYRIN REPEAT; DRUG CARRIERS; DRUG DESIGN; GENETIC THERAPY; HUMANS; MODELS, MOLECULAR; PEPTIDE LIBRARY; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84920848625     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010611-134654     Document Type: Review

References (134)

1. Forrer P, Stumpp MT, Binz HK, Pluckthun A. 2003. A novel strategy to design binding molecules harnessing the modular nature of repeat proteins. FEBS Lett. 539:2-6
2. Skerra A, Pluckthun A. 1988. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240:1038-41
3. Glockshuber R, Malia M, Pfitzinger I, Pluckthun A. 1990. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 29:1362-67
4. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. 1994. Making antibodies by phage display technology. Annu. Rev. Immunol. 12:433-55
5. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, et al. 2000. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296:57-86
6. Hanes J, Pluckthun A. 1997. In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. USA 94:4937-42
7. Hanes J, Jermutus L, Weber-Bornhauser S, Bosshard HR, Pluckthun A. 1998. Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proc. Natl. Acad. Sci. USA 95:14130-35
8. Ewert S, Honegger A, Pluckthun A. 2004. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods 34:184-99
9. Pluckthun A, Moroney SE. 2005. Modern antibody technology: the impact on drug development. In Modern Biopharmaceuticals, ed. J Knablein, pp. 1147-86. Weinheim:Wiley-VCH
10. Kobe B, Kajava AV. 2000. When protein folding is simplified to protein coiling: the continuum of solenoid protein structures. Trends Biochem. Sci. 25:509-15
11. Binz HK, Stumpp MT, Forrer P, Amstutz P, Pluckthun A. 2003. Designing repeat proteins: wellexpressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J. Mol. Biol. 332:489-503
12. Stumpp MT, Forrer P, Binz HK, Pluckthun A. 2003. Designing repeat proteins: modular leucine-rich repeat protein libraries based on the mammalian ribonuclease inhibitor family. J. Mol. Biol. 332:471-87
13. Pancer Z, Amemiya CT, Ehrhardt GR, Ceitlin J, Gartland GL, Cooper MD. 2004. Somatic diversification of variable lymphocyte receptors in the agnathan sea lamprey. Nature 430:174-80
14. Aderem A, Ulevitch RJ. 2000. Toll-like receptors in the induction of the innate immune response. Nature 406:782-87
15. Heidrich K, Blanvillain-Baufume S, Parker JE. 2012. Molecular and spatial constraints on NB-LRR receptor signaling. Curr. Opin. Plant Biol. 15:385-91
16. Pancer Z, Cooper MD. 2006. The evolution of adaptive immunity. Annu. Rev. Immunol. 24:497-518
17. Waterhouse RM, Povelones M, Christophides GK. 2010. Sequence-structure-function relations of the mosquito leucine-rich repeat immune proteins. BMC Genomics 11:531
18. Boersma YL, Pluckthun A. 2011. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr. Opin. Biotechnol. 22:849-57
19. Jost C, Pluckthun A. 2014. Engineered proteins with high specificity. Curr. Opin. Struct. Biol. 27:102-12
20. Bork P. 1993. Hundreds of ankyrin-like repeats in functionally diverse proteins: mobile modules that cross phyla horizontally? Proteins 17:363-74
21. Li J, Mahajan A, Tsai MD. 2006. Ankyrin repeat: A unique motifmediating protein-protein interactions. Biochemistry 45:15168-78
22. Walker RG, Willingham AT, Zuker CS. 2000. A Drosophila mechanosensory transduction channel. Science 287:2229-34
23. Sedgwick SG, Smerdon SJ. 1999. The ankyrin repeat: A diversity of interactions on a common structural framework. Trends Biochem. Sci. 24:311-16
24. Forrer P, Binz HK, Stumpp MT, Pluckthun A. 2004. Consensus design of repeat proteins. ChemBioChem 5:183-89
25. Virnekas B, Ge L, Pluckthun A, Schneider KC, Wellnhofer G, Moroney SE. 1994. Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis. Nucleic Acids Res. 22:5600-7
26. Pluckthun A. 2012. Ribosome display: A perspective. Methods Mol. Biol. 805:3-28
27. Steiner D, Forrer P, Pluckthun A. 2008. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. J. Mol. Biol. 382:1211-27
28. Interlandi G, Wetzel SK, Settanni G, Pluckthun A, Caflisch A. 2008. Characterization and further stabilization of designed ankyrin repeat proteins by combining molecular dynamics simulations and experiments. J. Mol. Biol. 375:837-54
29. Kramer MA, Wetzel SK, Pluckthun A, Mittl PR, Grutter MG. 2010. Structural determinants for improved stability of designed ankyrin repeat proteins with a redesigned C-capping module. J. Mol. Biol. 404:381-91
30. Wetzel SK, Ewald C, Settanni G, Jurt S, Pluckthun A, Zerbe O. 2010. Residue-resolved stability of full-consensus ankyrin repeat proteins probed by NMR. J. Mol. Biol. 402:241-58
31. Schilling J, Schoeppe J, Pluckthun A. 2014. From DARPins to LoopDARPins: novel LoopDARPin design allows the selection of low picomolar binders in a single round of ribosome display. J. Mol. Biol. 426:691-721
32. Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, et al. 2004. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat. Biotechnol. 22:575-82
33. Kohl A, Binz HK, Forrer P, Stumpp MT, Pl uckthun A, Grutter MG. 2003. Designed to be stable: crystal structure of a consensus ankyrin repeat protein. Proc. Natl. Acad. Sci. USA 100:1700-5
34. Tamaskovic R, Simon M, Stefan N, Schwill M, Pluckthun A. 2012. Designed ankyrin repeat proteins (DARPins): from research to therapy. Methods Enzymol. 503:101-34
35. Wetzel SK, Settanni G, Kenig M, Binz HK, Pluckthun A. 2008. Folding and unfolding mechanism of highly stable full-consensus ankyrin repeat proteins. J. Mol. Biol. 376:241-57
36. Binz HK, Kohl A, Pl uckthun A, Gr utter MG. 2006. Crystal structure of a consensus-designed ankyrin repeat protein: implications for stability. Proteins 65:280-84
37. Mattheakis LC, Bhatt RR, Dower WJ. 1994. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc. Natl. Acad. Sci. USA 91:9022-26
38. Hanes J, Jermutus L, Pluckthun A. 2000. Selecting and evolving functional proteins in vitro by ribosome display. Methods Enzymol. 328:404-30
39. Hanes J, Schaffitzel C, Knappik A, Pluckthun A. 2000. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol. 18:1287-92
40. Luginbuhl B, Kanyo Z, Jones RM, Fletterick RJ, Prusiner SB, et al. 2006. Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation. J. Mol. Biol. 363:75-97
41. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, et al. 2007. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J. Mol. Biol. 369:1015-28
42. Dreier B, Mikheeva G, Belousova N, Parizek P, Boczek E, et al. 2011. Her2-specificmultivalent adapters confer designed tropism to adenovirus for gene targeting. J. Mol. Biol. 405:410-26
43. Dreier B, Pluckthun A. 2010. Ribosome display, a technology for selecting and evolving proteins from large libraries. Methods Mol. Biol. 687:283-306
44. Amstutz P, Binz HK, Parizek P, Stumpp MT, Kohl A, et al. 2005. Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins. J. Biol. Chem. 280:24715-22
45. Zahnd C, Pecorari F, Straumann N, Wyler E, Pluckthun A. 2006. Selection and characterization of Her2 binding-designed ankyrin repeat proteins. J. Biol. Chem. 281:35167-75
46. Schweizer A, Roschitzki-Voser H, Amstutz P, Briand C, Gulotti-Georgieva M, et al. 2007. Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. Structure 15:625-36
47. Huber T, Steiner D, R othlisberger D, Pluckthun A. 2007. In vitro selection and characterization of DARPins and Fab fragments for the co-crystallization ofmembrane proteins: theNa+-citrate symporter CitS as an example. J. Struct. Biol. 159:206-21
48. Veesler D, Dreier B, Blangy S, Lichiere J, Tremblay D, et al. 2009. Crystal structure and function of a DARPin neutralizing inhibitor of lactococcal phage TP901-1: comparison of DARPin and camelid VHH binding mode. J. Biol. Chem. 384:30718-26
49. Stefan N, Martin-Killias P, Wyss-Stoeckle S, Honegger A, Zangemeister-Wittke U, Pluckthun A. 2011. DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. J. Mol. Biol. 413:826-43
50. Zahnd C, Sarkar CA, Pluckthun A. 2010. Computational analysis of off-rate selection experiments to optimize affinity maturation by directed evolution. Protein Eng. Des. Sel. 23:175-84
51. Siva AC, Kirkland RE, Lin B, Maruyama T, McWhirter J, et al. 2008. Selection of anti-cancer antibodies from combinatorial libraries by whole-cell panning and stringent subtraction with human blood cells. J. Immunol. Methods 330:109-19
52. Fekkes P, Driessen AJ. 1999. Protein targeting to the bacterial cytoplasmic membrane. Microbiol. Mol. Biol. Rev. 63:161-73
53. Bibi E. 2011. Early targeting events during membrane protein biogenesis in Escherichia coli. Biochim. Biophys. Acta 1808:841-50
54. Steiner D, Forrer P, Stumpp MT, Pluckthun A. 2006. Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display. Nat. Biotechnol. 24:823-31
55. Dr oge MJ, Boersma YL, Braun PG, Buining RJ, Julsing MK, et al. 2006. Phage display of an intracellular carboxylesterase of Bacillus subtilis: comparison of Sec and Tat pathway export capabilities. Appl. Environ. Microbiol. 72:4589-95
56. Paschke M, Hohne W. 2005. A twin-arginine translocation (Tat)-mediated phage display system. Gene 350:79-88
57. Nangola S, Minard P, Tayapiwatana C. 2010. Appraisal of translocation pathways for displaying ankyrin repeat protein on phage particles. Protein Expr. Purif. 74:156-61
58. Speck J, Arndt KM, M uller KM. 2011. Efficient phage display of intracellularly folded proteins mediated by the TAT pathway. Protein Eng. Des. Sel. 24:473-84
59. Pepper LR, Cho YK, Boder ET, Shusta EV. 2008. A decade of yeast surface display technology:Where are we now? Comb. Chem. High Throughput Screen. 11:127-34
60. Amstutz P, Koch H, Binz HK, Deuber SA, Pluckthun A. 2006. Rapid selection of specific MAP kinasebinders from designed ankyrin repeat protein libraries. Protein Eng. Des. Sel. 19:219-29
61. Kummer L, Parizek P, Rube P, Millgramm B, Prinz A, et al. 2012. Structural and functional analysis of phosphorylation-specific binders of the kinase ERK from designed ankyrin repeat protein libraries. Proc. Natl. Acad. Sci. USA 109:E2248-57
62. Parizek P, Kummer L, Rube P, Prinz A, Herberg FW, Pluckthun A. 2012. Designed ankyrin repeat proteins (DARPins) as novel isoform-specific intracellular inhibitors of c-Jun N-terminal kinases. ACS Chem. Biol. 7:1356-66
63. Kummer L, Hsu CW, Dagliyan O, MacNevin C, Kaufholz M, et al. 2013. Knowledge-based design of a biosensor to quantify localized ERK activation in living cells. Chem. Biol. 20:847-56
64. Gilbreth RN, Koide S. 2012. Structural insights for engineering binding proteins based on non-antibody scaffolds. Curr. Opin. Struct. Biol. 22:413-20
65. Bukowska MA, Grutter MG. 2013. New concepts and aids to facilitate crystallization. Curr. Opin. Struct. Biol. 23:409-16
66. Theurillat JP, Dreier B, Nagy-Davidescu G, Seifert B, Behnke S, et al. 2010. Designed ankyrin repeat proteins: A novel tool for testing epidermal growth factor receptor 2 expression in breast cancer. Mod. Pathol. 23:1289-97
67. Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, et al. 2010. Neonatal Fc receptor: from immunity to therapeutics. J. Clin. Immunol. 30:777-89
68. Simon M, Frey R, Zangemeister-Wittke U, Pl uckthun A. 2013. Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension. Bioconjug. Chem. 24:1955-66
69. Simon M, Stefan N, Borsig L, Pl uckthun A, Zangemeister-Wittke U. 2014. Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEGylation. Mol. Cancer Ther. 13:375-85
70. Chapman AP. 2002. PEGylated antibodies and antibody fragments for improved therapy: A review. Adv. Drug Deliv. Rev. 54:531-45
71. Kubetzko S, Sarkar CA, Pluckthun A. 2005. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol. Pharmacol. 68:1439-54
72. Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, et al. 2010. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res. 70:1595-605
73. Willuda J, Kubetzko S, Waibel R, Schubiger PA, Zangemeister-Wittke U, Pluckthun A. 2001. Tumor targeting of mono-, di- and tetravalent anti-p185HER-2 miniantibodies multimerized by self-associating peptides. J. Biol. Chem. 276:14385-92
74. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, et al. 1993. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 53:4026-34
75. Maeda H, Nakamura H, Fang J. 2013. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 65:71-79
76. Schmidt MM, Wittrup KD. 2009. Amodeling analysis of the effects ofmolecular size and binding affinity on tumor targeting. Mol. Cancer Ther. 8:2861-71
77. Thurber GM, Schmidt MM, Wittrup KD. 2008. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 60:1421-34
78. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, et al. 2001. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61:4750-55
79. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, et al. 2011. Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors. Cancer Res. 71:2250-59
80. Waibel R, Alberto R, Willuda J, Finnern R, Schibli R, et al. 1999. Stable one-step technetium-99m labeling ofHis-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat. Biotechnol. 17:897-901
81. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-82
82. Moasser MM. 2007. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26:6469-87
83. Verma S, Miles D, Gianni L, Krop IE, Welslau M, et al. 2012. Trastuzumab emtansine for HER2- positive advanced breast cancer. N. Engl. J. Med. 367:1783-91
84. Burris HA III, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, et al. 2011. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)- positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29:398-405
85. Kumler I, Tuxen MK, Nielsen DL. 2014. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat. Rev. 40:259-70
86. Lee SC, Srivastava RM, L opez-Albaitero A, Ferrone S, Ferris RL. 2011. Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol. Res. 50:248-54
87. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. 2004. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-28
88. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, et al. 1994. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269:14661-65
89. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, et al. 2009. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-40
90. Schaefer G, Fitzpatrick VD, Sliwkowski MX. 1997. γ-Heregulin: A novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175. Oncogene 15:1385-94
91. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, et al. 2011. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 71:1871-82
92. Finn RS, Slamon DJ. 2003. Monoclonal antibody therapy for breast cancer: Herceptin. Cancer Chemother. Biol. Response Modif. 21:223-33
93. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, et al. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:2639-48
94. Boersma YL, Chao G, Steiner D, Wittrup KD, Pluckthun A. 2011. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J. Biol. Chem. 286:41273-85
95. Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, Pluckthun A. 2013. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure 21:1979-91
96. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, et al. 2003. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756-60
97. Dawson JP, Bu Z, Lemmon MA. 2007. Ligand-induced structural transitions in ErbB receptor extracellular domains. Structure 15:942-54
98. Endres NF, Das R, Smith AW, Arkhipov A, Kovacs E, et al. 2013. Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 152:543-56
99. Arkhipov A, Shan Y, Das R, Endres NF, Eastwood MP, et al. 2013. Architecture and membrane interactions of the EGF receptor. Cell 152:557-69
100. Zuppinger C, Suter TM. 2010. Cancer therapy-associated cardiotoxicity and signaling in the myocardium. J. Cardiovasc. Pharmacol. 56:141-46
101. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG. 2010. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31:1913-21
102. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. 2007. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am. J. Pathol. 171:386-95
103. Biggers K, Scheinfeld N. 2008. VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer. Curr. Opin. Mol. Ther. 10:176-86
104. Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, et al. 2003. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin. Cancer. Res. 9:2837-48
105. Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U. 2006. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Mol. Cancer Ther. 5:3170-80
106. Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U. 2007. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol. Cancer Ther. 6:3019-27
107. Martin-Killias P, Stefan N, Rothschild S, Pluckthun A, Zangemeister-Wittke U. 2011. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin. Cancer. Res. 17:100-10
108. Alley SC, Okeley NM, Senter PD. 2010. Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14:529-37
109. Winkler J, Martin-Killias P, Pluckthun A, Zangemeister-Wittke U. 2009. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol. Cancer Ther. 9:2674-83
110. Salmon F, Grosios K, Petry H. 2014. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®). Expert Rev. Clin. Pharmacol. 7:53-65
111. Amalfitano A, Parks RJ. 2002. Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr. Gene Ther. 2:111-33
112. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, et al. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424:681-84
113. Yeh HH, Ogawa K, Balatoni J, Mukhapadhyay U, Pal A, et al. 2011. Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc. Natl. Acad. Sci. USA 108:1603-8
114. Beatty MS, Curiel DT. 2012. Chapter two-adenovirus strategies for tissue-specific targeting. Adv. Cancer Res. 115:39-67
115. Dreier B, Honegger A, Hess C, Nagy-Davidescu G, Mittl PR, et al. 2013. Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters. Proc. Natl. Acad. Sci. USA 110:E869-77
116. Forrer P, Chang C, Ott D, Wlodawer A, Pluckthun A. 2004. Kinetic stability and crystal structure of the viral capsid protein SHP. J. Mol. Biol. 344:179-93
117. Yanagi Y, Takeda M, Ohno S, Seki F. 2006. Measles virus receptors and tropism. Jpn. J. Infect. Dis. 59:1-5
118. Munch RC, M uhlebach MD, Schaser T, Kneissl S, Jost C, et al. 2011. DARPins: an efficient targeting domain for lentiviral vectors. Mol. Ther. 19:686-93
119. Friedrich K, Hanauer JR, Prufer S, Munch RC, Volker I, et al. 2013. DARPin-targeting ofmeasles virus: unique bispecificity, effective oncolysis, and enhanced safety. Mol. Ther. 21:849-59
120. Munch RC, Janicki H, Volker I, Rasbach A, Hallek M, et al. 2013. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol. Ther. 21:109-18
121. Stahl A, Stumpp MT, Schlegel A, Ekawardhani S, Lehrling C, et al. 2013. Highly potent VEGF-Aantagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. Angiogenesis 16:101-11
122. Syed BA, Evans JB, Bielory L. 2012. Wet AMD market. Nat. Rev. Drug Discov. 11:827
123. Campochiaro PA, Channa R, Berger BB, Heier JS, Brown DM, et al. 2013. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: A phase I/II study. Am. J. Ophthalmol. 155:697-704. e2
124. Wolf S, Souied EH, Mauget-Faysse M, Devin F, Patel M, et al. 2011. Phase I MP0112 Wet AMD study: results of a single escalating dose study with DARPinMP0112 in Wet AMD. Presented at Annu. Meet. Assoc. Res. Vis. Ophthalmology, May 2, Fort Lauderdale, FL, poster 1655
125. Souied EH, Devin F, Mauget-Faysse M, Kolar P, Wolf-Schnurrbusch U, et al. 2014. Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: A Phase I/II study. Am. J. Ophthalmol. 158:724-32. e2
126. Schilling J, Schoeppe J, Sauer E, Pluckthun A. 2014. Co-crystallization with conformation-specific designed ankyrin repeat proteins explains the conformational flexibility of BCL-W. J. Mol. Biol. 426:2346-61
127. Schroeder T, Barandun J, Flutsch A, Briand C, Mittl PR, Grutter MG. 2013. Specific inhibition of caspase-3 by a competitive DARPin: molecular mimicry between native and designed inhibitors. Structure 21:277-89
128. Pecqueur L, Duellberg C, Dreier B, Jiang Q, Wang C, et al. 2012. A designed ankyrin repeat protein selected to bind to tubulin caps the microtubule plus end. Proc. Natl. Acad. Sci. USA 109:12011-16
129. Gigant B, Wang W, Dreier B, Jiang Q, Pecqueur L, et al. 2013. Structure of a kinesin-tubulin complex and implications for kinesin motility. Nat. Struct. Mol. Biol. 20:1001-7
130. Eggel A, Baumann MJ, Amstutz P, Stadler BM, Vogel M. 2009. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. J. Mol. Biol. 393:598-607
131. Eggel A, Buschor P, Baumann MJ, Amstutz P, Stadler BM, Vogel M. 2011. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein. Allergy 66:961-68
132. Kim B, Eggel A, Tarchevskaya SS, Vogel M, Prinz H, Jardetzky TS. 2012. Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor. Nature 491:613-17
133. Mann A, Friedrich N, Krarup A, Weber J, Stiegeler E, et al. 2013. Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors. J. Virol. 87:5868-81
134. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. 2007. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol. Int. 27:269-74